



PTO/SB/08a (11-08)

Approved for use through 12/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 12

Complete if Known

Application Number	09/586,704-Conf. #7559
Filing Date	June 5, 2000
First Named Inventor	Ralph M. Steinman
Art Unit	1644
Examiner Name	R. B. Schwadron
Attorney Docket Number	RUJ-001CNRCE2

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1*	US-4,474,893	10-02-1984	Reading	
	A2*	US-4,946,778	08-07-1990	Ladner et al.	
	A3*	US-4,954,617	09-04-1990	Fanger et al.	
	A4*	US-5,455,030	10-03-1995	Ladner et al.	
	A5*	US-5,476,786	12-19-1995	Huston	
	A6*	US-5,545,807	08-13-1996	Surani et al.	
	A7*	US-5,869,057	02-09-1999	Rock	
	A8*	US-5,876,917	03-02-1999	Hart et al.	
	A9*	US-5,922,845	07-13-1999	Deo et al.	
	A10*	US-6,080,409	06-27-2000	Laus et al.	
	A11*	US-6,277,959	08-21-2001	Valladeau et al.	
	A12*	US-6,340,569	01-22-2002	Ball et al.	
	A13*	US-6,479,247-A1	11-12-2002	Hart et al.	
	A14*	US-20020187131-A1	12-12-2002	Hawiger et al.	
	A15*	US-6,756,478-A1	06-29-2004	Valladeau et al.	
	A16*	US-20040001853-A1	01-01-2004	George et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	B1	WO-86/01533-A1	03-13-1986	Celltech Limited		
	B2	WO-88/00052-A1	01-14-1988	Trustees of Dartmouth College		
	B3	WO-92/07579-A1	05-14-1992	The Children's Medical Center Corporation		
	B4	WO-92/03918-A1	03-19-1992	Genpharm International, Inc.		
	B5	WO-93/04187-A1	03-04-1993	Medical Research Council		
	B6	WO-93/12227-A1	06-24-1993	Genpharm International, Inc.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Express Mail Label No. EM 192 977 557 US Dated: February 23, 2009

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <h1>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h1> <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/586,704-Conf. #7559
				Filing Date	June 5, 2000
				First Named Inventor	Ralph M. Steinman
				Art Unit	1644
				Examiner Name	R. B. Schwadron
				Attorney Docket Number	RUJ-001CNRCE2
Sheet	5	of	12		

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ²
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	B25	WO-03/040169-A2	05-15-2003	Medarex Inc et al.		
	B26	WO-04/026326-A2	04-01-2004	Stichting Katholieke Universiteit		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. Applicant's unique citation designation number (optional). ² See Kinds Documents of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/586,704-Conf. #7559
				Filing Date	June 5, 2000
				First Named Inventor	Ralph M. Steinman
				Art Unit	1644
				Examiner Name	R. B. Schwadron
Sheet	6	of	12	Attorney Docket Number	RUJ-001CNRCE2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Apostolopoulos, Vasso et al, "Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses," <i>Vaccine</i> , Vol. 18:3174-3184 (2000)	
	C2	Berard, Frederic et al, "Cross-Priming of Naive CD8 T Cells against Melanoma Antigens Using Dendritic Cells Loaded with Killed Allogeneic Melanoma Cells," <i>J. Exp. Med.</i> , Vol. 192(11):1535-1543 (2000)	
	C3	Berlyn, Kathleen A. et al, "Generation of CD4 ⁺ and CD8 ⁺ T Lymphocyte Responses by Dendritic Cells Armed with PSA/Anti-PSA (Antigen/Antibody) Complexes," <i>Clinical Immunology</i> , Vol. 101(3):276-283 (2001)	
	C4	Bird, Robert E. et al, "Single-Chain Antigen-Binding Proteins," <i>Science</i> , Vol. 242(4877):423-426 (1988)	
	C5	Brennan, Maureen et al, "Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G1 Fragments," <i>Science</i> , Vol. 229:81-83 (1985)	
	C6	Casset, Florence et al., "A peptide mimetic of an anti-CD4 monoclonal antibody in rational design," <i>Biochemical and Biophysical Research Communications</i> , Vol. 307:198-205 (2003)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/586,704-Conf. #7559
				Filing Date	June 5, 2000
				First Named Inventor	Ralph M. Steinman
				Art Unit	1644
				Examiner Name	R. B. Schwadron
Sheet	7	of	12	Attorney Docket Number	RUJ-001CNRCE2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C7	Chen, Yvonne et al., "Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen," <i>J. Mol. Biol.</i> , Vol. 293:865-881 (1999)	
	C8	Chien, Nadine C. et al, "Significant structural and functional change of an antigen-binding site by a distant amino acid substitution: Proposal of a structural mechanism," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 86:5532-5536 (1989)	
	C9	Cox, John C. et al., "Adjuvants - a classification and review of their modes of action," <i>Vaccine</i> , Vol. 15(3):248-256 (1997)	
	C10	De Pascalis, Roberto et al., "Grafting of 'Abbreviated' Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody," <i>The Journal of Immunology</i> , Vol. 169:3076-3084 (2002)	
	C11	Frleta, Davor et al, "Class II-targeted antigen is superior to CD40-targeted antigen at stimulating humoral responses in vivo," <i>International Immunopharmacology</i> , Vol. 1:265-275 (2001)	
	C12	Galfre, G. et al, "Antibodies to major histocompatibility antigens produced by hybrid cell lines," <i>Nature</i> , Vol. 266(7):550-552 (1977)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/586,704-Conf. #7559
				Filing Date	June 5, 2000
				First Named Inventor	Ralph M. Steinman
				Art Unit	1644
				Examiner Name	R. B. Schwadron
Sheet	8	of	12	Attorney Docket Number	RUJ-001CNRCE2

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	C13	Geissmann, Frédéric et al, "A Subset of Human Dendritic Cells Expresses IgA Fc Receptor (CD89), Which Mediates Internalization and Activation Upon Cross-Linking by IgA Complexes," <i>The Journal of Immunology</i> , Vol. 166:346-352 (2001)		
	C14	Glennie, Martin J. et al, "Preparation and Performance of Bispecific F(ab') ₂ Antibody Containing Thioether-Linked Fab'γ Fragments," <i>The Journal of Immunology</i> , Vol. 139(7):2367-2375 (1987)		
	C15	Hawiger, Daniel et al, "Dendritic Cells Induce Peripheral T Cell Unresponsiveness Under Steady State Conditions In Vivo," <i>J. Exp. Med.</i> , Vol. 194(6):769-779 (2001)		
	C16	He, Li-Zhen et al, "A Novel Human Cancer Vaccine Elicits Cellular Responses to the Tumor-Associated Antigen, Human Chorionic Gonadotropin β," <i>Clinical Cancer Research</i> , Vol. 10:1920-1927 (2004)		
	C17	He, Lizhen et al, "An Antigen Presenting Cell-Targeted Cancer Vaccine that Elicits CD4 and CD8 Effector Responses to the hCGβ Tumor-Associated Antigen," <i>Proceedings of the American Association for Cancer Research</i> , Vol. 44, 2nd ed., pg. 167 (2003)		
	C18	Inaba, Kayo et al., "Tissue Distribution of the DEC-205 Protein That Is Detected by the Monoclonal Antibody NLDC-145, I. Expression on Dendritic Cells and Other Subsets of Mouse Leukocytes," <i>Cellular Immunology</i> , Vol. 163:148-156 (1995)		
	C19	Janeway, Charles A. Jr. et al., "Localized regions of hypervariable sequence form the antigen-binding site," <i>Immunobiology</i> , 6 th Edition, Garland Science, Chpt. 3, pgs. 110-112 (2004)		
	C20	Jiang, Wanping et al., "The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing," <i>Nature</i> , Vol. 375:151-155 (1995)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/586,704-Conf. #7559
				Filing Date	June 5, 2000
				First Named Inventor	Ralph M. Steinman
				Art Unit	1644
				Examiner Name	R. B. Schwadron
Sheet	9	of	12	Attorney Docket Number	RUJ-001CNRCE2

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	C21	Karpovsky, Boris et al, "Production of Target-Specific Effector Cells Using Hetero-Cross-Linked Aggregates Containing Anti-Target Cell and Anti-Fcγ Receptor Antibodies," <i>Journal of Experimental Medicine</i> , Vol. 160:1686-1701 (1984)		
	C22	Kawakami, Yutaka et al, "The Use of Melanosomal Proteins in the Immunotherapy of Melanoma," <i>Journal of Immunotherapy</i> , Vol. 21(4):237-246 (1998)		
	C23	Kobayashi, Hiroyuki et al, "Tryptophan H33 plays an important role in pyrimidine (6-4) pyrimidone photoproduct binding by a high-affinity antibody," <i>Protein Engineering</i> , Vol. 12(10):879-884 (1999)		
	C24	Lamminmäki, Urpo et al., "Crystal Structure of a Recombinant Anti-estradiol Fab Fragment in Complex with 17β-Estradiol," <i>The Journal of Biological Chemistry</i> , Vol. 276(39):36687-36694 (2001)		
	C25	Liu, Margaret A. et al, "Heteroantibody duplexes target cells for lysis by cytotoxic T lymphocytes," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 82:8648-8652 (1985)		
	C26	Lonberg, Nils et al, "Antigen-specific human antibodies from mice comprising four distinct genetic modifications," <i>Nature</i> , Vol. 368:856-859 (1994)		
	C27	MacCallum, Robert M. et al., "Antibody-antigen Interactions: Contact Analysis and Binding Site Topography," <i>J. Mol. Biol.</i> , Vol. 262:732-745 (1996)		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
				Application Number	09/586,704-Conf. #7559
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Filing Date	June 5, 2000
				First Named Inventor	Ralph M. Steinman
				Art Unit	1644
				Examiner Name	R. B. Schwadron
				Attorney Docket Number	RUJ-001CNRCE2
Sheet	10	of	12		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C28	McKown, Kevin M. et al., "Lack of Efficacy of Oral Bovine Type II Collagen Added to Existing Therapy in Rheumatoid Arthritis," <i>Arthritis & Rheumatism</i> , Vol. 42 (6):1204-1208 (1999)	
	C29	Mestas, Javier et al., "Of Mice and Not Men: Differences between Mouse and Human Immunology," <i>The Journal of Immunology</i> , Vol. 172:2731-2738 (2004)	
	C30	Monteiro, Renato C. et al, "Molecular Heterogeneity of Fcα Receptors Detected by Receptor-Specific Monoclonal Antibodies," <i>The Journal of Immunology</i> , Vol. 148(6):1764-1770 (1992)	
	C31	Noorman, Femke et al, "Monoclonal antibodies against the human mannose receptor as a specific marker in flow cytometry and immunohistochemistry for macrophages," <i>Journal of Leukocyte Biology</i> , Vol. 61:63-72 (1997)	
	C32	Nossal, "Immunologic Tolerance," <i>Fundamentals of Immunology</i> , 2 nd Edition, Paven Press Ltd., W.E. Paul (Ed.), Chpt. 19, pgs. 571-586 (1989)	
	C33	Nouri-Shirazi, Mahyar et al, "Dendritic Cells Capture Killed Tumor Cells and Present Their Antigens to Elicit Tumor-Specific Immune Response," <i>The Journal of Immunology</i> , Vol. 165:3797-3803 (2000)	
	C34	Paulus, H., "Preparation and Biomedical Applications of Bispecific Antibodies," <i>Behring Inst. Mitt.</i> , Vol. 78:118-132 (1985)	
	C35	Potter, Kathleen N. et al, "Evidence for Involvement of a Hydrophobic Patch in Framework Region 1 of Human V4-34-Encoded Igs in Recognition of the Red Blood Cell I Antigen," <i>The Journal of Immunology</i> , Vol. 169:3777-3782 (2002)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/586,704-Conf. #7559
				Filing Date	June 5, 2000
				First Named Inventor	Ralph M. Steinman
				Art Unit	1644
				Examiner Name	R. B. Schwadron
Sheet	11	of	12	Attorney Docket Number	RUJ-001CNRCE2

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	C36	Ramakrishna, Vanky et al, "Mannose Receptor Targeting of Tumor Antigen pmel17 to Human Dendritic Cells Directs Anti-Melanoma T Cell Responses via Multiple HLA Molecules," <i>The Journal of Immunology</i> , Vol. 172:2845-2852 (2004)		
	C37	Ramakrishna, Venky et al, "Synergistic Role of TLR Agonists in T Cell-Mediated Immunity Induced by Mannose Receptor Antibody Targeting of Tumor Antigens to Human DCs," <i>J. Immunother.</i> , Vol. 28(6):658 (2005)		
	C38	Rudikoff, Stuart et al, "Single amino acid substitution altering antigen-binding specificity," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 79:1979-1983 (1982)		
	C39	Sallusto, Federica et al, "Dendritic Cells Use Macropinocytosis and the Mannose Receptor to Concentrate Macromolecules in the Major Histocompatibility Complex Class II Compartment: Downregulation by Cytokines and Bacterial Products," <i>J. Exp. Med.</i> , Vol. 182:389-400 (1995)		
	C40	Spack, E.G., "Antigen-specific therapies for the treatment of multiple sclerosis: a clinical trial update," <i>Expert Opin. Investig. Drugs</i> , Vol. 6(11):1715-1727 (1997)		
	C41	Swiggard, William J. et al., "DEC-205, a 205-kDa Protein Abundant on Mouse Dendritic Cells and Thymic Epithelium That is Detected by the Monoclonal Antibody NLDC-145: Purification, Characterization, and N-Terminal Amino Acid Sequence," <i>Cellular Immunology</i> , Vol. 165:302-311 (1995)		
	C42	Taylor, Lisa D. et al., "A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins," <i>Nucleic Acids Research</i> , Vol. 20(23):6287-6295 (1992)		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
				Application Number	09/586,704-Conf. #7559
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Filing Date	June 5, 2000
				First Named Inventor	Ralph M. Steinman
				Art Unit	1644
				Examiner Name	R. B. Schwadron
				Attorney Docket Number	RUJ-001CNRCE2
Sheet	12	of	12		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C43	Tempest, Philip R. et al, "A Humanized Anti-Tumor Necrosis Factor- α Monoclonal Antibody That Acts as a Partial, Competitive Antagonist of the Template Antibody," <i>Hybridoma</i> , Vol. 13(3):183-190 (1994)	
	C44	Tjoa, Benjamin A. et al, "Development of dendritic-cell based prostate cancer vaccine," <i>Immunology Letters</i> , Vol. 74:87-93 (2000)	
	C45	Tufveson, G. et al., "New Immunosuppressants: Testing and Development in Animal Models and the Clinic: with Special Reference to DSG," <i>Immunological Reviews</i> , Vol. 136(1):99-109 (1993)	
	C46	Tüting, Thomas et al, "Autologous Human Monocyte-Derived Dendritic Cells Genetically Modified to Express Melanoma Antigens Elicit Primary Cytotoxic T Cell Responses In Vitro: Enhancement by Cotransfection of Genes Encoding the Th1-Biasing Cytokines IL-12 and IFN- α ," <i>The Journal of Immunotherapy</i> , Vol. 160:1139-1147 (1998)	
	C47	Wallace, Paul K. et al, "Exogenous antigen targeted to Fc γ RI on Myeloid cells is presented in association with MHC class I," <i>Journal of Immunological Methods</i> , Vol. 248:183-194 (2001)	
	C48	Wang, Hui et al, "Rapid antibody responses by low-dose, single-step, dendritic cell-targeted immunization," <i>PNAS</i> , Vol. 96(2):847-852 (2000)	
	C49	Ward, E. Sally et al, "Binding activities of a repertoire of single immunoglobulin variable domains secreted from <i>Escherichia coli</i> ," <i>Nature</i> , Vol. 341:544-546 (1989)	
	C50	You, Zhaoyang et al, "Targeting Dendritic Cells to Enhance DNA Vaccine Potency," <i>Cancer Research</i> , Vol. 61:3704-3711 (2001)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.